Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers

Boehringer headquarters Boehringer headquarters, Ingelheim, Germany Boehringer Ingelheim is committed to improving outcomes for people facing aggressive cancers where there are currently few treatment optionsDAREON®-Lung-1 and DAREON®-NEC-1 will evaluate obrixtamig as a DLL3 biomarker-informed approach designed to help identify patients and inform treatment decisions for small cell lung cancer (SCLC) and extrapulmonary neuroendocrine carcinoma (epNEC)1,2Beamion LUNG-3 will explore zongertinib in